Pulmonary Renal Syndrome Treatment Market Size, Share, and Growth Forecast, 2026 - 2033

The global pulmonary renal syndrome treatment market size is likely to be valued at US$0.6 billion in 2026 and is expected to reach US$0.9 billion by 2033, growing at a CAGR of 5.5% between 2026 and 2033, driven by increasing recognition of ANCA-associated vasculitis, anti-GBM disease, and other autoimmune conditions associated with pulmonary-renal syndrome. Advances in B-cell-directed therapies, biologics, plasma exchange, and steroid-sparing treatment strategies are expanding the therapeutic landscape.

Pulmonary-renal syndrome is a clinical syndrome characterized primarily by the combination of diffuse alveolar hemorrhage and glomerulonephritis. It is associated with several autoimmune and inflammatory diseases, including ANCA-associated vasculitis, anti-glomerular basement membrane disease, and systemic lupus erythematosus. Because the underlying causes and clinical severity vary considerably, treatment typically requires a combination of immunosuppressive therapy, corticosteroids, supportive care, and, in selected patients, plasma exchange or renal replacement therapy.

Drivers - Expanding Diagnosis and Recognition of Immune-Mediated Pulmonary-Renal Disease

Improved recognition of ANCA-associated vasculitis and other autoimmune causes of pulmonary-renal syndrome is expanding the number of patients entering specialist treatment pathways. AAV has a pooled global incidence of approximately 17.2 cases per million person-years, while prevalence is estimated at approximately 198 cases per million. Country-level studies also demonstrate substantial variation.

Research in Germany has identified meaningful prevalence of granulomatosis with polyangiitis and microscopic polyangiitis, while population-based research in England has reported AAV incidence above 30 cases per million person-years in certain regions. Greater availability of ANCA testing, renal biopsy, advanced imaging, and multidisciplinary assessment improves identification of patients who may previously have been diagnosed late or incorrectly.

Shift toward Targeted and Steroid-Sparing Treatment

Treatment guidelines increasingly emphasize controlling disease activity while limiting cumulative exposure to corticosteroids and cytotoxic medicines. The 2024 KDIGO recommendations incorporate evidence supporting lower-dose glucocorticoid regimens, rituximab, complement-pathway inhibition, and selective use of plasma exchange. The American College of Rheumatology and Vasculitis Foundation also conditionally recommends rituximab over cyclophosphamide for remission induction in severe active granulomatosis with polyangiitis and microscopic polyangiitis. This evolution is shifting treatment toward therapies designed around specific immune mechanisms rather than broad immunosuppression alone.

Targeted therapies can capture value from established treatment categories when they demonstrate improved safety, reduced steroid exposure, durable remission, or improved renal outcomes. Manufacturers with strong evidence in organ-threatening disease have opportunities to establish differentiated positions in specialist treatment pathways.

Restraint - Treatment Complexity, Safety Risks, and High Monitoring Requirements

Pulmonary-renal syndrome often requires urgent treatment involving several specialties and treatment modalities. Patients may require high-dose corticosteroids, immunosuppressants, biologic therapy, plasma exchange, respiratory support, dialysis, or transplantation depending on disease severity. These interventions increase healthcare resource requirements and expose patients to significant infection, metabolic, infusion-related, and organ-specific risks. Regulatory concerns have also demonstrated the commercial risks associated with targeted therapies. In 2026, U.S. regulators reported 76 cases of drug-induced liver injury associated with avacopan, including serious outcomes and deaths, highlighting the importance of long-term pharmacovigilance.

Opportunities - Expansion of Specialty Care Across Asia Pacific

Asia Pacific provides substantial long-term growth potential because diagnosis and treatment infrastructure are developing from a comparatively lower base. China has a significant AAV population and a disease profile characterized by a relatively high proportion of microscopic polyangiitis and MPO-ANCA positivity. India is also developing a stronger specialist treatment network. A recent Indian tertiary-center cohort reported respiratory involvement in 79.3% of AAV patients and renal involvement in 65.5%, demonstrating the relevance of pulmonary and renal complications within the regional disease burden.

India's renal-care infrastructure also continues to expand. The national dialysis program covers 36 States and Union Territories, more than 750 districts, and more than 1,900 dialysis centers, providing a broader supportive-care platform for patients who develop severe renal complications.

Emergence of Advanced B-Cell and Cellular Therapies

The treatment landscape is progressing beyond conventional cytotoxic therapy toward B-cell depletion, complement-pathway modulation, and potentially cellular immunotherapy. Novartis is evaluating rapcabtagene autoleucel, a CD19-directed CAR-T therapy, in a Phase 2 study involving severe active granulomatosis with polyangiitis and microscopic polyangiitis. The study began in 2025 and is planned to enroll 126 adults.

The development of cellular therapies is particularly significant because severe autoimmune disease may eventually be treated through deep and potentially durable immune-system modification rather than repeated maintenance dosing.

Treatment Modality Insights

Immunosuppressive therapy is anticipated to account for approximately 46.7% of the market share. Its position reflects the central role of immune suppression in severe pulmonary-renal disease, particularly ANCA-associated vasculitis (AAV). Rituximab and cyclophosphamide remain established induction options, often combined with corticosteroids. For example, rituximab is widely used for severe granulomatosis with polyangiitis and microscopic polyangiitis. Biosimilar availability, established hospital protocols, and physician familiarity further support segment demand.

Plasmapheresis or plasma exchange is anticipated to be the fastest-growing treatment-modality segment. Its use is concentrated among high-risk patients with severe renal impairment, anti-GBM disease, or significant pulmonary hemorrhage. For example, plasma exchange remains particularly relevant in anti-GBM disease with severe kidney involvement and selected AAV cases with a high risk of kidney failure. Expansion of apheresis services in tertiary hospitals is supporting treatment capacity.

Drug Class Insights

Immunosuppressive drugs are anticipated to hold approximately 47.9% of the market share. Cyclophosphamide, rituximab, and mycophenolate remain important because they directly address the autoimmune mechanisms underlying pulmonary and renal injury. Rituximab is particularly significant in severe AAV, while biosimilar versions are improving access and increasing price competition.

Corticosteroids are anticipated to be the fastest-growing drug-class segment. Prednisolone and methylprednisolone remain central to acute disease control and are commonly administered with rituximab or cyclophosphamide. For example, intravenous methylprednisolone is frequently used during severe acute presentations, followed by oral corticosteroid therapy. Growth reflects sustained treatment requirements, although clinical practice increasingly emphasizes lower cumulative steroid exposure.

North America Pulmonary Renal Syndrome Treatment Market Trends

North America is the leading regional market, accounting for approximately 37.8% of market share in 2026. The United States drives regional demand through its concentration of tertiary hospitals, specialist nephrology and rheumatology centers, advanced apheresis services, biologic distribution networks, and clinical research infrastructure.

AstraZeneca's Fasenra (benralizumab) provides a contrasting example of successful targeted innovation in the broader pulmonary vasculitis landscape. FDA approval for eosinophilic granulomatosis with polyangiitis (EGPA) in 2024 expanded biologic treatment options for a pulmonary-involving vasculitic disease, with the MANDARA trial demonstrating remission outcomes and corticosteroid reduction. The region's large renal-care ecosystem further supports specialist capacity, while investment remains focused on biologics, rare-disease development, advanced diagnostics, apheresis, and steroid-sparing therapies.

United States Pulmonary Renal Syndrome Treatment Market Trends

The United States represents the region's primary commercial and innovation hub. Its large network of academic medical centers enables rapid adoption of specialist therapies, clinical-trial participation, and multidisciplinary management of severe pulmonary and renal complications. The regulatory experience with avacopan is likely to make safety monitoring and evidence quality increasingly important for future targeted products.

Europe Pulmonary Renal Syndrome Treatment Market Trends

Europe represents a mature market supported by specialist vasculitis centers, nephrology networks, established biologic access, and harmonized pharmaceutical regulation. Germany, the United Kingdom, France, and Spain provide important treatment and research markets, although differences in healthcare financing and disease prevalence influence country-level adoption.

The region's biologic market is being shaped by both innovation and biosimilar competition. Rituximab biosimilars have expanded treatment availability while increasing pricing pressure and encouraging healthcare systems to prioritize cost-effective immunosuppression. At the same time, AstraZeneca's Fasenra received EU approval for EGPA in October 2024, adding another targeted biologic option for pulmonary-involving vasculitis and strengthening the role of steroid-sparing approaches.

The European market also experienced a major setback for targeted AAV treatment in 2026. The European Commission revoked TAVNEOS' marketing authorization on August 4, 2026, following an EMA review that concluded its benefits were no longer proven to outweigh its risks. This development strengthens the relative importance of established immunosuppressants, biosimilars, and alternative targeted therapies.

Germany Pulmonary Renal Syndrome Treatment Market Trends

Germany remains an important European market because of its specialist nephrology infrastructure, established AAV treatment centers, and strong pharmaceutical research environment. The country's emphasis on evidence-based prescribing and healthcare efficiency also creates opportunities for biosimilars, while innovative therapies must demonstrate meaningful clinical value to secure broader adoption.

U.K. Pulmonary Renal Syndrome Treatment Market Trends

The U.K. benefits from a coordinated specialist-care ecosystem and strong clinical research capabilities. National health-system purchasing places considerable emphasis on cost-effectiveness, making biosimilar rituximab and therapies capable of reducing hospitalizations, renal deterioration, or long-term corticosteroid exposure particularly relevant to future market development.

Asia Pacific Pulmonary Renal Syndrome Treatment Market Trends

Asia Pacific is likely to be the fastest-growing regional market, supported by expanding diagnostic capacity, increasing specialist access, large patient populations, renal-care investment, and pharmaceutical manufacturing capabilities. China has a substantial AAV treatment base, with MPA and MPO-ANCA-positive disease particularly relevant, while Japan has a mature renal-care system and extensive dialysis infrastructure.

China Pulmonary Renal Syndrome Treatment Market Trends

China represents a major long-term opportunity as access to ANCA testing, renal biopsy, tertiary nephrology services, and biologic therapies expands. Greater diagnostic recognition can increase the number of patients receiving appropriate immunosuppressive treatment, making market growth increasingly dependent on treatment penetration as well as disease prevalence. Expansion of domestic pharmaceutical manufacturing and biosimilar capabilities can further improve affordability and access.

Japan Pulmonary Renal Syndrome Treatment Market Trends

Japan combines sophisticated nephrology care with extensive renal replacement infrastructure and a mature pharmaceutical market. Its established specialist network supports management of severe renal manifestations and creates an attractive environment for advanced biologics and targeted therapies. Japan's experience with complex renal disease also supports demand for dialysis equipment, hospital-based immunosuppression, and specialist monitoring.

India Pulmonary Renal Syndrome Treatment Market Trends

India provides a distinct infrastructure-led growth opportunity. The Pradhan Mantri National Dialysis Programme had reached 36 States/Union Territories, 751 districts, and 1,925 centers by August 2026, demonstrating substantial expansion of renal-care capacity. This infrastructure does not specifically target pulmonary-renal syndrome, but it improves the healthcare system's ability to manage patients who progress to severe renal failure.

Indian pharmaceutical companies also contribute to regional affordability through generic and biosimilar manufacturing. As access to rituximab, corticosteroids, diagnostic testing, plasma exchange, and renal replacement care improves, the region's growth opportunity increasingly centers on earlier diagnosis, treatment accessibility, specialist capacity, and cost-efficient therapies rather than disease prevalence alone.

 

The global pulmonary-renal syndrome treatment market is moderately consolidated at the branded-therapy level but fragmented across the broader treatment ecosystem. Roche and Pfizer have strong positions through established rituximab products, while other pharmaceutical companies participate through targeted immunology, corticosteroids, biosimilars, and supportive therapies. Novartis is strengthening its long-term position through cellular immunotherapy development. Companies operating in dialysis and apheresis also contribute to the broader treatment ecosystem.

Market participants are focusing on targeted immunology, steroid-sparing treatment, biosimilar development, geographic expansion, and clinical evidence generation. Differentiation increasingly depends on renal outcomes, remission durability, safety, treatment convenience, and total cost of care. Emerging strategies include hospital partnerships, specialist-center engagement, outpatient treatment models, advanced diagnostics, and lifecycle management of biologic products.

Key Industry Developments:

• In April 2026, Amgen disclosed that the U.S. FDA had proposed withdrawing TAVNEOS (avacopan), its targeted therapy for severe active ANCA-associated vasculitis, from the U.S. market.
• In July 2026, Amgen submitted supporting materials to the FDA following its request for a hearing regarding the proposed withdrawal of TAVNEOS, maintaining that the therapy has a favorable benefit-risk profile for patients with severe active ANCA-associated vasculitis.